MIMEDX GROUP INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-K
Period ended 2023-12-31; filed 2024-02-28.
0001376339-24-000009
Item 1A. Summary of Risk FactorsCurrent report: 10-K
Period ended 2024-12-31; filed 2025-02-26.
0001376339-25-000009
Item 1A. Summary of Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 44 previous paragraphs and 44 current paragraphs.
34 unchanged; 8 reworded; 2 added; 2 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (2)
Current report
•The FDA has in the past determined, and may in the future determine, that certain of our products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361 of the Public Health Service Act (“Section 361”), and may require that we revise our labeling and marketing claims for these products or that we suspend sales of such products until FDA pre-market clearance or approval is obtained, which could adversely affect our business, results of operations, and financial condition.
Current report
•The restrictive covenants in the Citizens Credit Agreement, and the Company’s obligation to make payments under the Citizens Credit Agreement, limit our operating and financial flexibility.
Removed paragraphs (2)
Previous report
•In the future, certain of our products may no longer qualify for regulation as human cells, tissues and cellular and tissue-based products solely under Section 361 of the Public Health Service Act, which could result in removal of the applicable products from the market, making the introduction of new tissue products more expensive, significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements. Additional regulatory requirements may be imposed in the future.
Previous report
•Our indebtedness may adversely affect our financial health.
Reworded paragraphs (8)
Previous wording
•Our products depend on the availability of tissue from human donors, and any disruption in supply could adversely affect our business.
Current wording
•Many of our products depend on the availability of tissue from human donors, and any disruption in supply could adversely affect our business.
Previous wording
•We depend on our senior leadership team and may not be able to retain or replace these employees or recruit additional qualified personnel.
Current wording
•We depend on our senior leadership team and key employees and may not be able to retain or replace these employees or recruit additional qualified personnel.
Previous wording
•We contract with independent sales agents and distributors.
Current wording
•We contract with and are dependent on independent sales agents and distributors.
Previous wording
•Disruption of our processing could adversely affect our business, financial condition and results of operations.
Current wording
•Disruption of our processing facilities could adversely affect our business, financial condition and results of operations.
Previous wording
•To be commercially successful, we must convince physicians, where appropriate, how and when our products are proper alternatives to existing treatments and that our products should be used in their procedures.
Current wording
•To be commercially successful, we must educate physicians, where appropriate, how and when our products are proper alternatives to existing treatments and that our products should be used in their procedures.
Previous wording
•The products we manufacture and process are derived from human tissue and therefore have the potential for disease transmission.
Current wording
•The products we offer are derived from human and animal tissue and therefore have the potential for disease transmission.
Previous wording
•Obtaining and maintaining the necessary regulatory approvals for certain of our products will be expensive and time consuming and may impede our ability to fully exploit our technologies.
Current wording
•Obtaining and maintaining the necessary regulatory approvals, including conducting clinical trials, for certain of our products will be expensive and time consuming and may impede our ability to fully exploit our technologies.
Previous wording
•Federal and state laws that protect the privacy and security of personal information may increase our costs and limit our ability to collect and use that information and subject us to liability if we are unable to fully comply with such laws.
Current wording
•Federal, state, and international laws that protect the privacy and security of personal information may increase our costs and limit our ability to collect and use that information and subject us to liability.